Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96T52
UPID:
IMP2L_HUMAN
Alternative names:
IMP2-like protein
Alternative UPACC:
Q96T52; Q75MF1; Q75MN9; Q75MP0; Q75MS5; Q75MS8; Q96HJ2
Background:
Mitochondrial inner membrane protease subunit 2, also known as IMP2-like protein, plays a crucial role in mitochondrial function. It catalyzes the removal of transit peptides, facilitating the targeting of proteins from the mitochondrial matrix across the inner membrane into the inter-membrane space. A key substrate of this protease is the nuclear-encoded protein DIABLO, integral to apoptosis regulation.
Therapeutic significance:
Given its involvement in Gilles de la Tourette syndrome, a neurologic disorder characterized by motor and vocal tics, understanding the role of Mitochondrial inner membrane protease subunit 2 could lead to novel therapeutic strategies for managing this complex condition.